# A Study Comparing Two Magnetic Resonance Imaging (MRI) Contrast Agents in MRI of the Brain

> **NCT00323102** · PHASE4 · COMPLETED · sponsor: **Bracco Diagnostics, Inc** · enrollment: 114 (—)

## Conditions studied

- Brain Pathology

## Interventions

- **DRUG:** Multihance

## Key facts

- **NCT ID:** NCT00323102
- **Lead sponsor:** Bracco Diagnostics, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-05
- **Primary completion:** —
- **Final completion:** 2007-03
- **Target enrollment:** 114 (—)
- **Last updated:** 2008-01-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00323102

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00323102, "A Study Comparing Two Magnetic Resonance Imaging (MRI) Contrast Agents in MRI of the Brain". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00323102. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*